Table 4.
Treatment-emergent adverse events reported in ≥5 % of subjects in the teduglutide group
| Variable, n (%) | Placebo (n = 13) | Teduglutide 4 mg (n = 23) |
|---|---|---|
| Treatment-emergent AEs |
9 (69) |
14 (61) |
| Abdominal distention |
2 (15) |
8 (35) |
| Constipation |
2 (15) |
5 (22) |
| Headache |
2 (15) |
5 (22) |
| Abdominal pain |
1 (8) |
5 (22) |
| Nausea |
0 |
5 (22) |
| Dyspepsia |
0 |
2 (9) |
| Eructation |
0 |
2 (9) |
| Extremity pain | 0 | 2 (9) |
AE = adverse event.